MASH曾名为非酒精性脂肪性肝炎（NASH），是代谢功能障碍相关脂肪性肝病（MAFLD）的晚期形式。MASH是导致肝脏相关死亡的主要原因，对全球卫生系统造成日益加重的负担。此外，MASH患者，特别是那些具有更多代谢风险因素（高血压、合并2型糖尿病）的 ...

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...

Bagsværd, Denmark Tuesday, November 5, 2024, 10:00 Hrs [IST] ...

ESSENCE is a double-blinded, 240-week study that involves 1,200 adults with MASH and stage two or three liver fibrosis.

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced promising results from the first part of its ESSENCE ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a phase 3, 240-week, double-blinded trial ...

参考资料： [1] Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superiorimprovement in both liver fibrosis and MASH resolution in the ESSENCE trial.Retrieved November 1, 2024 from https ...

Study participants were randomly assigned 2:1 to receive once-weekly subcutaneous semaglutide 2.4mg or placebo alongside standard of care. The primary endpoints for part 1 were resolution of ...